RAPT Therapeutics, Inc. RAPT · Stock Open RAPT Therapeutics, Inc. in new tab
RAPT Therapeutics, Inc. Analysis (RAPT)
Is RAPT Therapeutics, Inc. a good investment? RAPT Therapeutics, Inc. (RAPT) is currently trading at 58.01 USD.
Earnings Schedule: RAPT Therapeutics, Inc. is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is -2.71.
Investor FAQ
Does RAPT Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is RAPT Therapeutics, Inc.?
RAPT Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of -11.66.
Company Profile
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
| Split Date | Split Ratio to 1 |
|---|---|
| June 17, 2025 | 0.12 |
Community Discussion